XJPX
4554
Market cap289mUSD
Oct 09, Last price
1,780.00JPY
1D
1.83%
1Q
-6.02%
Jan 2017
31.85%
Name
Fuji Pharma Co Ltd
Chart & performance
P/E
15.50
P/S
0.90
EPS
114.86
Div yield, %
2.60%
Shrs. gr., 5y
-4.77%
Rev. gr., 5y
8.87%
Revenues
51.68b
+12.01%
Net income
3.00b
-51.20%
CFO
5.80b
+39.75%
Dividend
Sep 29, 202626 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Key people
Shuhei Morita
President, Chief Executive Officer, Representative Director · since 2024
Toyoyuki Kamide
Vice President, Chief Director of Business Administration, Director · since 2025
Atsuya Mitsuhashi
Managing Executive Officer, Director of Business Planning · since 2024
Masayuki Naganawa
Managing Executive Officer, Chief Director of Research and Development · since 2024
Sachiko Matsuyama
Executive Officer, Director of Production Planning · since 2025
Takahiro Nozaki
Executive Officer, Chief Director of Production · since 2025
Kazuhisa Sakurai
Executive Officer, Chief Director of Reliability Assurance · since 2025
Hiroshi Uji
Executive Officer, Director of Business Administration · since 2020
Hitoshi Yokoyama
Executive Officer, Chief Director of Pharmaceutical Business · since 2025
Takayuki Iwai
Chairman of the Board, Representative Director · since 2024
Satoshi Suzuki
Vice President, Chief Director of Business Strategy, Director · since 2022
Keiji Hirai
Independent Director · since 2016
Kiyohisa Hirano
Independent Director · since 2025
Keiko Kiyama
Independent Director · since 2020
Independent Director · since 2025
Minoru Ozawa
Independent Director · since 2024
Headquarters & legal address
千代田区三番町５番地７
東京都, 13 102-0075
JP
東京都, 13 102-0075
JP
Other language
Fuji Pharma Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||